Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sintilimab plus chemotherapy vs placebo plus chemotherapy in first-line advanced gastric or gastroesophageal junction adenocarcinoma
CTR20181953Phase 3Completed
- Sponsor
- Innovent Biologics
- Start
- Nov 2018
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 3 trial of sintilimab in gastric adenocarcinoma, gastroesophageal junction adenocarcinoma, sponsored by Innovent Biologics. Started Nov 2018; status: completed.
02
Drugs
sintilimab
03
Conditions
gastric adenocarcinomagastroesophageal junction adenocarcinoma
Beyond the preview
Go deeper on CTR20181953.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20181953.